coteau ARQ.

ETRA New listing

Electra Therapeutics, Inc.
IPO · listed Sep 18, 2026
$8.71
−$0.54 (5.84%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-36%-26%-15%-5%+5%Sep 18Oct 23Oct 552w low $8.50
ETRASPY
Wall St. Highest PT $36.00 (+313.3%) Wall St. Avg PT $34.00 (+290.4%)
$9$19$29$39$49POC $9Hi $36Avg $34
Underwater Drawdown %Max DD -38.1%Current -37.4%
0.0%-38.1%
Relative Strength vs SPY-34.0% vs SPYUnderperforming
+43%0%-43%
1W
−$0.04 (0.46%)
1M
−$3.96 (31.25%)
3M
–
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
4 analysts · mean score 1.20
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$8.71
Average target$34.00
+$25.29 (+290.4%) upsideaverage target vs current price
CurrentAverageMedian
Low$32.00
Median$34.00
High$36.00
12-month Wall Street target range
Recent analyst rating changes · 5
Initiated
2026-10-22 · JP Morgan started covering ETRA at Overweight
Initiated
2026-10-13 · Jefferies started covering ETRA at Buy
Initiated
2026-10-13 · Evercore ISI Group started covering ETRA at Outperform
Initiated
2026-10-13 · TD Cowen started covering ETRA at Buy
Initiated
2026-10-13 · Cantor Fitzgerald started covering ETRA at Overweight
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$546.7M
P/E (next 12 months, estimated)-4.8
52-week range$8.50 – $15.50
Dividend yieldNo dividend
Analyst consensusStrong Buy (4)
Average analyst price target$34.00 (+290%)

What they do

Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells.

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for ETRA yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

ETRA earningsNo upcoming date on file
Source: Yahoo Finance · refreshed 2026-10-24 02:53:56 ET
No EPS history available.

News & catalysts

More news
XYZ's Square Adds Etra & Cafe Telegrama as Restaurant Momentum Builds
Zacks · Oct 01
Oura Shows How Shaky the IPO Market Really Is
Barrons.com · Sep 30
Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering
GlobeNewswire · Sep 17
Eleanor Yeh: Etra Fine Jewellery and the Art of Meaningful Ownership
PR Newswire · Aug 20
Rating changes
Initiated
2026-10-22 · JP Morgan started covering ETRA at Overweight
Initiated
2026-10-13 · Jefferies started covering ETRA at Buy
Initiated
2026-10-13 · Evercore ISI Group started covering ETRA at Outperform
Initiated
2026-10-13 · TD Cowen started covering ETRA at Buy
Initiated
2026-10-13 · Cantor Fitzgerald started covering ETRA at Overweight

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 02:53:56 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026